Современные подходы к лечению рвоты беременных: обзор клинических рекомендаций

Цель. Оценить актуальные подходы к лечению рвоты беременных на основании современных клинических рекомендаций.

Основные положения. Тошнота, рвота, снижение аппетита и изменение вкусовых ощущений — частые спутники беременности. Такие расстройства встречаются у 80-90% женщин. В большинстве случаев они не требуют медицинского вмешательства. Однако у некото­рых пациенток развивается тяжелая рвота (hyperemesis gravidarum). Это состояние опасно для матери и плода, поэтому требуется его активное лечение.

Заключение. Анализ российских и международных рекомендаций по медикаментозному лечению рвоты беременных показал согласо­ванность и приверженность к единым подходам к выбору терапии, основанным на принципах ее безопасности, этапности и индивидуа­лизации.

1. Gadsby R., Rawson V., Dziadulewicz E., Rousseau B. et al. Nausea and vomiting of pregnancy and resource implications: the NVP Impact Study. Br. J. Gen. Pract. 2019;69(680):e217–23. DOI: 10.3399/bjgp18X700745

2. Gadsby R., Barnie-Adshead A.M., Jagger C. A prospective study of nausea and vomiting during pregnancy. Br. J. Gen. Pract. 1993;43(371):245– 8. Erratum in: Br. J. Gen. Pract. 1993;43(373):325.

3. Brown H.L. Nausea and vomiting of pregnancy. Contemp. Ob. Gyn. 2016;61(4):48–50.

4. Kramer J., Bowen A., Stewart N., Muhajarine N. Nausea and vomiting of pregnancy. MCN Am. J. Matern. Child Nurs. 2013;38(1):21–7. DOI: 10.1097/NMC.0b013e3182748489

5. Gadsby R., Ivanova D., Trevelyan E., Hutton J.L. et al. Nausea and vomiting in pregnancy is not just ‘morning sickness’: data from a prospective cohort study in the UK. Br. J. Gen. Pract. 2020;70(697):e534–9. DOI: 10.3399/bjgp20X710885

6. Jansen L.A.W., Koot M.H., Van’t Hooft J., Dean C.R. et al. The Windsor definition for hyperemesis gravidarum: a multistakeholder international consensus definition. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021;266:15–22. DOI: 10.1016/j.ejogrb.2021.09.004

7. Garg R., Sanjay, Das V., Usman K. et al. Spontaneous pneumothorax: an unusual complication of pregnancy — a case report and review of literature. Ann. Thorac. Med. 2008;3(3):104–5. DOI: 10.4103/1817-1737.41915

8. Joshi A., Chadha G., Narayanan P. From discomfort to distress: a critical analysis of hyperemesis gravidarum in the emergency room. Cureus. 2023;15(8):e44004. DOI: 10.7759/cureus.44004

9. Goodwin T.M., Montoro M., Mestman J.H. Transient hyperthyroidism and hyperemesis gravidarum: clinical aspects. Am. J. Obstet. Gynecol. 1992;167(3):648–52. DOI: 10.1016/s0002-9378(11)91565-8

10. Fejzo M.S., Sazonova O.V., Sathirapongsasuti J.F., Hallgrímsdóttir I.B. et al. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat. Commun. 2018;9(1):1178. DOI: 10.1038/s41467-018-03258-0

11. Fejzo M., Arzy D., Tian R., MacGibbon K. et al. Evidence GDF15 plays a role in familial and recurrent hyperemesis gravidarum. Geburtshilfe Frauenheilkd. 2018;78(09):866–70. DOI: 10.1055/a-0661-0287

12. Fejzo M., Rocha N., Cimino I., Lockhart S. et al. Fetally-encoded GDF15 and maternal GDF15 sensitivity are major determinants of nausea and vomiting in human pregnancy. bioRxiv [Preprint]. 2023:2023.06.02.542661. DOI: 10.1101/2023.06.02.542661

13. Fejzo M.S., MacGibbon K.W., First O., Quan C. et al. Whole-exome sequencing uncovers new variants in GDF15 associated with hyperemesis gravidarum. BJOG. 2022;129(11):1845–52. DOI: 10.1111/1471-0528.17129

14. Nelson-Piercy C., Dean C., Shehmar M., Gadsby R. et al. The management of nausea and vomiting in pregnancy and hyperemesis gravidarum (Green-top Guideline No. 69). BJOG. 2024;131(7):e1– 30. DOI: 10.1111/1471-0528.17739

15. Veenendaal M.V.E., van Abeelen A.F.M., Painter R.C., van der Post J.A.M. et al. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG. 2011;118(11):1302– 13. DOI: 10.1111/j.1471-0528.2011.03023.x

16. Tan A., Foran T., Henry A. Managing nausea and vomiting in pregnancy in a primary care setting. Aust. Fam. Physician. 2016;45(8):564–8.

17. Depue R.H., Bernstein L., Ross R.K., Judd H.L. et al. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. Am. J. Obstet. Gynecol. 1987;156(5):1137–41. DOI: 10.1016/0002-9378(87)90126-8

18. Rhodes V.A., McDaniel R.W. The index of nausea, vomiting, and retching: a new format of the index of nausea and vomiting. Oncol. Nurs. Forum. 1999;26(5):889–94.

19. Rhodes V.A., Watson P.M., Johnson M.H. Development of reliable and valid measures of nausea and vomiting. Cancer Nurs. 1984;7(1):33–41.

20. Koren G., Boskovic R., Hard M., Maltepe C. et al. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am. J. Obstet. Gynecol. 2002;186(5 suppl. understanding):S228–31. DOI: 10.1067/mob.2002.123054

21. Koren G., Piwko C., Ahn E., Boskovic R. et al. Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J. Obstet. Gynaecol. 2005;25(3):241–4. DOI: 10.1080/01443610500060651

22. Lacasse A., Rey E., Ferreira E., Morin C. et al. Validity of a modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy. Am. J. Obstet. Gynecol. 2008;198(1):71.e1–7. DOI: 10.1016/j.ajog.2007.05.051

23. Ebrahimi N., Maltepe C., Bournissen F.G., Koren G. Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. J. Obstet. Gynaecol. Can. 2009;31(9):803–7. DOI: 10.1016/S1701-2163(16)34298-0

24. MacGibbon K.W., Kim S., Mullin P.M., Fejzo M.S. HyperEmesis Level Prediction (HELP Score) identifies patients with indicators of severe disease: a validation study. Geburtshilfe Frauenheilkd. 2021;81(1):90–8. DOI: 10.1055/a-1309-1997

25. Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., ред. Акушерство: национальное руководство. 2-е изд. М.: ГЭОТАРМедиа; 2022. 1080 с.

26. Ezberci İ., Güven E.S.G., Ustüner I., Sahin F.K. et al. Disability and psychiatric symptoms in hyperemesis gravidarum patients. Arch. Gynecol. Obstet. 2014;289(1):55–60. DOI: 10.1007/s00404-013-2934-5

27. Koot M.H., Grooten I.J., Post J.A.M.V., Bais J.M.J. et al. Ketonuria is not associated with hyperemesis gravidarum disease severity. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020;254 315–20. DOI: 10.1016/j.ejogrb.2020.08.014

28. Mitchell-Jones N., Gallos I., Farren J., Tobias A. et al. Psychological morbidity associated with hyperemesis gravidarum: a systematic review and meta-analysis. BJOG. 2017;124(1):20–30. DOI: 10.1111/1471-0528.14180

29. Fiaschi L., Nelson-Piercy C., Gibson J., Szatkowski L. et al. Adverse maternal and birth outcomes in women admitted to hospital for hyperemesis gravidarum: a population-based cohort study. Paediatr. Perinat. Epidemiol. 2018;32(1):40–51. DOI: 10.1111/ppe.12416

30. Petry C.J., Ong K.K., Beardsall K., Hughes I.A. et al. Vomiting in pregnancy is associated with a higher risk of low birth weight: a cohort study. BMC Pregnancy Childbirth. 2018;18(1):133. DOI: 10.1186/s12884-018-1786-1

31. Jarvis S., Nelson-Piercy C. Management of nausea and vomiting in pregnancy. BMJ. 2011;342:d3606. DOI: 10.1136/bmj.d3606

32. Koren G., Hankins G.D.V., Clark S., Caritis S.N. et al. Effectiveness of doxylamine-pyridoxine for morning sickness. Am. J. Obstet. Gynecol. 2016;214(5):664–6. DOI: 10.1016/j.ajog.2016.01.186

33. Erick M., Cox J.T., Mogensen K.M. ACOG Practice Bulletin 189: nausea and vomiting of pregnancy. Obstet. Gynecol. 2018;131(5):935. DOI: 10.1097/AOG.0000000000002604

34. Smith J.A., Fox K.A., Clark S.M. Nausea and vomiting of pregnancy: treatment and outcome. UptoDate 2023. URL: https://www.uptodate.com/contents/nausea-and-vomiting-of-pregnancy-treatment-andoutcome#H21389680 (дата обращения — 15.04.2025).

35. Figueroa Gray M., Hsu C., Kiel L., Dublin S. Getting through the day: a pilot qualitative study of U.S. women’s experiences making decisions about anti-nausea medication during pregnancy. BMC Pregnancy Childbirth. 2018;18(1):475. DOI: 10.1186/s12884-018-2093-6

36. Widnes S.F., Schjøtt J. Risk perception regarding drug use in pregnancy. Am. J. Obstet. Gynecol. 2017;216(4):375–8. DOI: 10.1016/j.ajog.2016.12.007

37. Monograph U. Use of ondansetron in pregnancy. 2019.

38. Jennings L.K., Mahdy H. Hyperemesis gravidarum [Internet]. StatPearls. 2022.

39. Pacei F., Tesone A., Laudi N., Laudi E. et al. The relevance of thiamine evaluation in a practical setting. Nutrients. 2020;12(9):2810. DOI: 10.3390/nu12092810

40. Hayakawa S., Nakajima N., Karasaki-Suzuki M., Yoshinaga H. et al. Frequent presence of helicobacter pylori genome in the saliva of patients with hyperemesis gravidarum. Am. J. Perinatol. 2000;17(5):243–8. DOI: 10.1055/s-2000-10005

41. Niemeijer M.N., Grooten I.J., Vos N., Bais J.M.J. et al. Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2014;211(2):150.e1–15. DOI: 10.1016/j.ajog.2014.02.012

42. Regan L.A., Hoffman R.S., Nelson L.S. Slower infusion of metoclopramide decreases the rate of akathisia. Am. J. Emerg. Med. 2009;27(4):475– 80. DOI: 10.1016/j.ajem.2008.03.044

43. Boelig R.C., Barton S.J., Saccone G., Kelly A.J. et al. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. J. Matern. Fetal Neonatal Med. 2018;31(18):2492–505. DOI: 10.1080/14767058.2017.1342805

44. Grooten I.J., Vinke M.E., Roseboom T.J., Painter R.C. A systematic review and meta-analysis of the utility of corticosteroids in the treatment of hyperemesis gravidarum. Nutr. Metab. Insights. 2015;8(suppl.1):23– 32. DOI: 10.4137/NMI.S29532

45. O’Brien B., Relyea M.J. Use of indigenous explanations and remedies to further understand nausea and vomiting during pregnancy. Health Care Women Int. 1999;20(1):49–61. DOI: 10.1080/073993399245953

46. Bustos M., Venkataramanan R., Caritis S. Nausea and vomiting of pregnancy — what’s new? Auton. Neurosci. 2017;202:62–72. DOI: 10.1016/j.autneu.2016.05.002

47. Basirat Z., Moghadamnia A.A., Kashifard M., Sarifi-Razavi A. The effect of ginger biscuit on nausea and vomiting in early pregnancy. Acta Med. Iran. 2009;47(1):51–6.

48. Vandraas K.F., Vikanes A.V., Vangen S., Magnus P. et al. Hyperemesis gravidarum and birth outcomes-a population-based cohort study of 2.2 million births in the Norwegian Birth Registry. BJOG. 2013;120(13):1654–60. DOI: 10.1111/1471-0528.12429

49. Koch K.L. Gastrointestinal factors in nausea and vomiting of pregnancy. Am. J. Obstet. Gynecol. 2002;186(5 suppl. understanding):S198–203. DOI: 10.1067/mob.2002.122598

50. Nijsten K., Dean C., van der Minnen L.M., Bais J.M.J. et al. Recurrence, postponing pregnancy, and termination rates after hyperemesis gravidarum: follow up of the MOTHER study. Acta Obstet. Gynecol. Scand. 2021;100(9):1636–43. DOI: 10.1111/aogs.14197

51. O’Hara M. Experience of hyperemesis gravidarum in a subsequent pregnancy. MIDIRS Midwifery Digest. 2017;27:309–18.

52. Sanghvi U., Thankappan K.R., Sarma P.S., Sali N. Assessing potential risk factors for child malnutrition in rural Kerala, India. J. Trop. Pediatr. 2001;47(6):350–5. DOI: 10.1093/tropej/47.6.350

53. Liu S., Rouleau J., Joseph K.S., Sauve R. et al. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J. Obstet. Gynaecol. Can. 2009;31(7):611–20. DOI: 10.1016/S1701-2163(16)34240-2

54. Pope E., Maltepe C., Koren G. Comparing pyridoxine and doxylamine succinate-pyridoxine HCl for nausea and vomiting of pregnancy: a matched, controlled cohort study. J. Clin. Pharmacol. 2015;55(7):809– 14. DOI: 10.1002/jcph.480

55. Doxylamine/pyridoxine for nausea and vomiting in pregnancy. Drug Ther. Bull. 2019;57(3):38–41. DOI: 10.1136/dtb.2018.000053

56. Шохин И.Е., Носков С.М., Глобенко А.А., Багаева Н.С. и др. Исследование фармакокинетических параметров и безопасности лекарственного препарата Дуоника после приема пищи в сравнении с оригинальной комбинацией доксиламина и пиридоксина. Фармакокинетика и фармакодинамика. 2024;2:3–11. DOI: 10.37489/2587-7836-2024-2-3-11